A First-in-human, Phase I/II, Open-label, Multi-center, Dose-Escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors
Details
This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.
Eligibility
You can join if...
Inclusion Criteria:
Adequate organ function
Life expectancy >= 12 weeks
Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734
Exclusion Criteria:
Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734
Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
An active hepatitis B/C infection
Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability